text:
SA News • Tue, Nov. 25
52wk high:
52wk low:
PE (ttm):
Div Rate:
Market Cap:
Be smarter and faster with PRO Alerts on MRK
SA News • Tue, Nov. 25
SA News • Tue, Nov. 25 • 24 Comments
SA News • Fri, Nov. 21 • 15 Comments
Vuru • Thu, Nov. 20 • 2 Comments
SA News • Mon, Nov. 17
SA News • Mon, Nov. 17 • 5 Comments
SA News • Tue, Nov. 11
SA News • Tue, Nov. 11 • 2 Comments
From other sites
at Nasdaq.com (Wed, 9:44AM)
at CNBC.com (Wed, 3:34AM)
at Zacks.com (Tue, 4:30PM)
at CNBC.com (Mon, 1:28PM)
at Zacks.com (Nov 20, 2014)
at CNBC.com (Nov 20, 2014)
at Nasdaq.com (Nov 20, 2014)
at Nasdaq.com (Nov 20, 2014)
at Zacks.com (Nov 19, 2014)
at Zacks.com (Nov 19, 2014)
There is research on this stock available only to PRO subscribers.
Medical Breakthroughs On The Horizon For MerckVuru • Thu, Nov. 20 • 2 Comments
- Merck (MRK) is a global health care company that includes prescription medicines; vaccines, biologic therapies, animal health and consumer care products.
- 3Q results overshadowed Keytruda receiving a broad breakthrough therapy designation for advanced NSCLC that's progressed after platinum-based chemotherapy.
- The Oct 2013 restructuring has laid a foundation for better than anticipated EPS growth as faster than expected cost cuts will place an upward bias to MRK's EPS outlook.
Merck Can Still Offer Healthy Doses Of Profits, Despite Disappointing ResultsWall Street Playbook • Tue, Oct. 28
- Merck is still making money, despite the revenue miss.
- With a yield of 3.10% and having just been granted approval for a key drug by the FDA, now is the wrong time to lose faith.
- The best play here is to add to an existing long position and wait for Merck to complete its transformation.
Merck In Q3: Some Side Effects May OccurKurt Avard • Mon, Oct. 27
- Merck will likely see a lacking Q3 report.
- Stock ticker rise may herald great opportunity, but also some risk in the short term as earnings slide.
- Company is looking to acquire new value to strengthen its presence in existing pharmaceutical markets.
- I don't believe the risk/reward ratio right now offers a good opportunity to put the stock in my portfolio.
- The dividend is a solid 3.11% but it's not really a dividend growth name.
- The stock appears to be extremely expensive on earnings growth expectations.
Merck Still Looks Very ExpensiveStock Traders Daily • Tue, Oct. 14 • 8 Comments
- Merck shares have fallen recently.
- Some investors think the stock looks like a bargain.
- But the smart money seems to think something else.
Merck: Be Prepared For A Buying Opportunity From A Dividend PerspectiveStock Gamer • Tue, Oct. 14 • 3 Comments
- Merck has a potential to sustain a 4% annual dividend growth while still being able to maintain steady free cash flow and earnings payout level.
- Current price implies a 2.75% perpetual dividend growth, which is well below the near-term growth potential and consensus long-term EPS growth estimate.
- A dividend discount model suggest the share price is near an attractive buying zone.
How Significant Can Keytruda Be For Merck?Trefis • Fri, Oct. 3 • 5 Comments
- In this analysis, we will estimate Keytruda's revenue generating potential.
- The overall melanoma patient count in the U.S. is estimated at a little over 640,000.
- If Merck can grab even 10% of the addressable patient pool, Keytruda can earn close to $5 billion in annual revenues.
Why Is Merck Running To 52-Week Highs Again? ESMO Conference This WeekendPharma Doc • Thu, Sep. 25 • 2 Comments
- Recent key approval of Keytruda, a high profile immuno-oncology drug for metastatic melanoma will be the talk of the ESMO conference this weekend in Madrid, Spain.
- Merck will report late breaking clinical data on Pembrolizumab in 5 tumor types this weekend.
- Merck will report out Phase III clinical data of (MK-5172/MK-8742) in Hepatitis C Genotype 1 patients by YE 2014.
The FDA Said It Has Granted Accelerated Approval To Merck's KeytrudaIs - Is Merck Worth Investing In?FNF Solutions • Tue, Sep. 23 • 7 Comments
- After seven years of waiting Merck has finally landed the FDA's approval on a cancer treatment drug.
- In layman terms, the drug stops cancer cells from attaching themselves to a protein and make diseased cells appear normal and healthy to the antibodies present in the immune system.
- Keytruda's lifesaving potential is not the only thing that has renewed stakeholder faith in the fledgling pharmaceutical giant.
- After losing big guns like Clarinex, Singulair, Propecia and Cozaar to patent protection, the company was unable to recover from the setback.
- Considering the company's new momentum the stock is expected to show upside potential in the upcoming quarters.
Riding Merck: The Conservative Aggressive Pharmaceutical Stock Of The YearPharma Doc • Tue, Sep. 9 • 5 Comments
- Merck is up 22% YTD with further upside to go.
- Merck is conservative because it's a blue chip that pays an annual dividend of 3.1% and has a diversified portfolio.
- Merck is an aggressive play with 20%-30% upside based on its potential for an all-oral Hepatitis C combo regimen and its new immuno-oncology drug, Keytruda.
Merck Vs. Pfizer: Merck Better Performer, Pfizer Better Risk-RewardBrian Gilmartin, CFA • Tue, Sep. 9 • 20 Comments
- Valuation metrics are very similar.
- Slight edge to Merck on expected earnings growth.
- Slight edge to Pfizer on dividend yield and cash flow valuation.
Merck: Should You Buy It?Balanced Investing • Mon, Aug. 11 • 11 Comments
- Top line shrinked by 1% in the second quarter due to the continued generic erosion. However, disciplined expense management prevented the decline from trickling down to the bottom line.
- The company has narrowed down its R&D focus on businesses that uphold the strength to become market leaders.
- Sale of consumer care segment to Bayer AG against a consideration of $14.2 billion, which can be invested in areas where Merck has a competitive edge.
- Merck has recently taken over Idenix Pharmaceuticals where the company's drug, nucleotide, was the crown jewel for Merck in this acquisition.
- Merck upholds solid future growth prospects, is undervalued and offers a higher than industry dividend yield of 3.16%.
Merck - Current Valuation Is Based On Future Pipeline, Amidst Poor Current Earnings QualityThe Value Investor • Tue, Aug. 5 • 3 Comments
- Merck reported earnings last week which were largely in line with expectations.
- This is as the company is in transformation: boosting its pipeline and cut costs to prepare for meaningful and continued growth.
- Given the poor quality of current GAAP earnings, a lot of the valuation is tied to the potential of the pipeline.
Why Merck Is Heading To $65Wall Street Playbook • Mon, Jul. 28 • 8 Comments
- Management has not lost focus. Merck has a plan to attack and grow its share in immuno-oncologyand entering/dominating the hepatitis C (HCV) and vaccines market.
- Management continues to offset the near-term weakness with growth in diabetes, immunology and anti-infective drugs.
- Given that analysts' highest price target currently stands at $70, I believe the companyshould be able to reach $65 per share in the next 12 to 18 months.
- We pitch two companies from the pharmaceutical sector, Merck and AbbVie, against one another in the latest installment of our Head-To-Head series.
- The article focuses on the relative strengths and weaknesses of Merck and AbbVie based on business performance and sustainability/dividends/forecasts.
- It ends with discussion of the current valuations of the two companies, and details whether Merck represents good relative value at current price levels.
Merck & Co. Inc.: I'm Long, But It Screams Overvalued TodayDouglas Denhartog • Wed, Jul. 23 • 20 Comments
- MRK is the single most expensive company in the DJIA by price to earnings, nearly double the DJIA's median of 18.4.
- Merck's current earnings payout ratio is nearly 116%.
- I am long Merck but do not recommend purchasing shares of MRK at today's prices.
Bad Times Continue To Hit Merck's Animal Health SegmentBalanced Investing • Tue, Jul. 22 • 2 Comments
- Merck continues to face major hindrances in its efforts to reintroduce Zilmax in the market.
- Withdrawal of Zilmax plopped down the animal health segment's contribution by almost 5% on a year-over-year basis.
- However, the research has been procrastinated for now as meatpackers continue to remain unconfident about selling beef produced during the company's research.
- In the meanwhile, companies like Eli Lilly are fully leveraging on this market opportunity to sell its substitute drug, Optaflexx.
- It may take a while before Merck is able to regain its lost market share and reputation in the beef industry.
- Merck is hovering around a 52-week high and the stock is up 30% from its recent trough.
- Merck is one of our "stocks to watch" in the Healthcare sector.
- Merck has raised its quarterly dividend 3 times in the past 11 quarters.
What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck?Trefis • Fri, Jun. 27 • 14 Comments
- Merck's legacy products are facing declining revenues due to competitive pressure from generics.
- To offset weakness in its legacy products and some other drugs, Merck is banking on its R&D pipeline.
- Merck recently announced a definitive agreement to acquire Idenix at $24.50 a share for cash, offering a hefty premium of about 240% over last Friday's (i.e. June 6th) closing price.
Why Did Merck Pay Such A Huge Premium For IdenixTrefis • Wed, Jun. 11 • 6 Comments
- Merck recently announced a definitive agreement to acquire Idenix at $24.50 a share.
- The acquisition will strengthen Merck's Hepatits C portfolio and help it stem the revenue decline resulting from patent expiry of major drugs.
- Idenix currently has three Hepatitis C drugs under development.
5 Dividend Stocks Working Hard During The HolidaysDividends4Life • Today, 8:02 AM
Gilead's Value Without Its Hep C FranchiseTim Harrison • Tue, Nov. 18 • 56 Comments
Sanofi: Recent Plunge Is A Buying OpportunityNicholas Kitonyi • Tue, Nov. 18 • 22 Comments
The Post AASLD Annual Meeting Hepatitis C LandscapeLeonard Yaffe • Fri, Nov. 14 • 7 Comments
When Is It Time To Accumulate Theravance?Chris Lau • Tue, Nov. 11 • 19 Comments
Are Expensive Biotech Drugs Bad For Business?Keith Williams • Tue, Nov. 11 • 7 Comments
Dulled Dow Dogs Dodge Downsides In NovemberFredrik Arnold • Mon, Nov. 10 • 5 Comments
Merck & Co Inc. Discusses Q3 2013 Results (Webcast)Oct. 28, 2013
Tue, Nov. 25, 1:42 PM
- OncoSec Medical (OTCQB:ONCS +13.5%) and the University of California, San Francisco enter into a clinical collaboration to evaluate the safety, tolerability and efficacy of the combination of Merck's (MRK +0.6%) Keytruda (pembrolizumab) and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma.
- Immunopulse is an investigational intratumoral therapy that uses plasmid DNA that encodes for Interleukin-12 and delivers it directly into the tumor via a proprietary electroporation device.
- The collaboration will be a Phase 2 trial that will commence in Q1 2015. Merck will supply pembrolizumab and OncoSec will supply the electroporation devices and plasmid IL-12.
Tue, Nov. 25, 1:07 PM
- Merck (NYSE:MRK) declares $0.45/share quarterly dividend, 2.27% increase from prior dividend of $0.44.
- Forward yield 3.02%
- Payable Jan 8; for shareholders of record Dec. 15; ex-div Dec. 11.
Tue, Nov. 25, 8:18 AM
- Pharmacy benefits manager Express Scripts (NASDAQ:ESRX) is at the forefront of an increasing wave of resistance to the high prices of new drugs from pharma and biotech firms, some which cost as much as $50K per month. Pharmaceutical spending in the U.S. is $270B and may breach $500B in five years. ESRX's method of controlling costs is to refuse to pay for them. For 2015, for example, it is excluding 66 branded drugs from its main formulary, an increase of 18 from 2014's 48. On the list is Johnson & Johnson's (NYSE:JNJ) rheumatoid arthritis drug Simponi (golimumab) which costs $3K per month.
- Other prescription benefits managers are employing similar tactics. CVS Health (NYSE:CVS) will exclude 95 drugs from its 2015 formulary including Pfizer's (NYSE:PFE) multiple sclerosis med Rebif (interferon beta-1a) which costs $5K for a four-week supply.
- Governments are pushing back as well. Among 42 state Medicaid programs, 27 pay for Gilead Sciences' HCV med Sovaldi (sofosbuvir) only for patients with severe liver damage while others impose coverage limitations for patients with recent substance-abuse problems. In the U.S., the full regimen cost is $84K. Recently, Britain's National Institute for Health and Care Excellence (NICE) balked at recommending reimbursement for Roche's (OTCQX:RHHBY) blood cancer drug Gazyvaro (obinutuzumab).
- Ninety percent of commercial health plans require pre-approval of specialty drugs, up from 82% in 2011.
- Previously: Roche's Gazyvaro not NICE in the UK
- Previously: Global drug tab will breach trillion dollar mark this year
- ETFs: IBB, BIB, IRY, BIS, IXJ, DRGS
- Related tickers: (NYSE:NVS) (NYSE:AZN) (NASDAQ:AMGN) (NASDAQ:BIIB) (NASDAQ:CELG) (NYSE:LLY) (NYSE:SNY) (NYSE:ABT) (NYSE:ABBV) (NYSE:BMY) (NYSE:MRK) (NYSE:GSK)
Mon, Nov. 24, 9:59 AM
- Merck (MRK -0.5%) submits a new drug application to the Japanese Pharmaceuticals and Medicinal Devices Agency for omarigliptin for the treatment of type 2 diabetes. Japan is the first country with a regulatory filing for the drug candidate.
- Omarigliptin is a once-weekly DPP-4 inhibitor. Merck's Januvia (sitagliptin), approved by the FDA in 2006, was the first agent in the class to achieve regulatory clearance.
Mon, Nov. 24, 9:48 AM
- Merck (MRK -0.7%) enters into an exclusive worldwide license agreement with NewLink Genetics (NLNK +0.5%) to develop and commercialize the latter's investigational rVSV-EBOV (Ebola) vaccine candidate.
- Phase 1 trials are currently underway at Walter Reed Army Institute of Research and the NIAID at the NIH. If successful, the NIH will commence a large, randomized Phase 3 study to evaluate the safety and efficacy of rVSV-EBOV and another investigational Ebola vaccine candidate co-developed by the National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline (GSK -0.3%).
- The rVSV-EBOV vaccine was created by scientists at the Public Health Agency of Canada's National Microbiology Laboratory.
Mon, Nov. 24, 8:40 AM
- Tetraphase Pharmaceuticals (NASDAQ:TTPH) is reportedly considering selling itself after being approached by interested suitors. Sources say the acquirer could be Acetelion (OTCPK:ALIOF) (OTC:ALIOY) or Roche (OTCQX:RHHBY).
- The attraction is Tetraphase's antibiotic eravacycline, currently in Phase 3 development. Both oral and IV formulations of the drug have demonstrated higher dose response rates than Johnson & Johnson's (NYSE:JNJ) Levaquin (levofloxacin) for the treatment of complicated urinary tract infections. In the Ignite-2 study, patients receiving 200 mg eravacycline IV-to-oral doses achieved a response rate of 70.8% while patients receiving 250 mg IV-to-oral doses achieved 64.3%, both significantly ahead of Levaquin's 52.2% response rate.
- A trial comparing eravacycline to Merck's (NYSE:MRK) Invanz (ertapenem) for the treatment of complicated intra-abdominal infections is underway.
- TTPH is up 18% premarket on light volume.
- Previously: Tetraphase completes eravacycline Phase 3 enrollment
Fri, Nov. 21, 8:48 AM
- The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion supporting approval of AbbVie's (NYSE:ABBV) Viekirax (a combination of ombitasvir, paritaprevir and ritonavir) plus Exviera (dasabuvir), with or without ribavirin, for patients with chronic HCV genotype 1 infection and Viekirax only, with ribavirin, for patients with HCV genotype 4 infection. A final decision by the European Commission usually takes about 60 days.
- The FDA tagged Viekirax a Breakthrough Therapy and granted priority review of AbbVie's NDA in June.
- Related tickers: (NASDAQ:ENTA) (NASDAQ:GILD) (NYSE:MRK) (NYSE:BMY) (NASDAQ:RGLS) (NASDAQ:CNAT) (NASDAQ:ACHN)
- Previously: Enanta declines HCV drug co-development option with AbbVie
- Previously: AbbVie presents HCV/HIV and liver transplant HCV data
Mon, Nov. 17, 3:59 PM
- In a Phase 2 clinical trial, Merck's (MRK +0.7%) anti-PD-1 therapy, Keytruda (pembrolizumab), improved progression-free survival (PFS) versus chemotherapy in patients with ipilimumab-refractory advanced melanoma. At six months, PFS for the 2 mg/kg and 10 mg/kg doses was 34% and 38%, respectively, compared to 16% for chemo (p<0.0001).
- Study results, including secondary endpoints, were presented today by Dr. Antoni Ribas, professor, Hematology/Oncology and Surgery, UCLA at the Society of Melanoma Research 2014 Congress in Zurich, Switzerland.
- The study's co-primary endpoints are PFS and overall survival (OS). Investigators will evaluate OS in 2015.
- Keytruda is approved in the U.S. at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Mon, Nov. 17, 1:02 PM
- In a Phase 3 trial, patients receiving Merck's (MRK +0.9%) Vytorin (ezetimibe/simvastatin) experienced fewer major cardiovascular events than those receiving simvastatin alone. In the study, called Improve-It, at seven years, 32.7% of patients taking Vytorin experienced a primary endpoint event compared to 34.7% of patients taking simvastatin alone (p=0.016) (hazard ratio: 0.936).
- Based on the LDL-cholesterol range in the study's treatment arms, the 6.4% relative risk reduction observed in the Vytorin arm was consistent with the treatment effect that had been projected based on prior studies of statins.
- The company intends to submit the data to the FDA to support a new indication for the reduction on major cardiovascular events for Vytorin and Zetia (ezetimibe).
Mon, Nov. 17, 4:06 AM
- Pfizer (NYSE:PFE) will pay $850M for rights to a cancer drug being developed by Merck (NYSE:MRK), puncturing investor expectations of a renewed bid for AstraZeneca (NYSE:AZN).
- As a result of the upfront payment, Pfizer has lowered its forecast of 2014 EPS to $1.40-$1.49 from $1.50-$1.59.
- The agreement also calls for Pfizer to pay as much as $2B to Merck if the immunotherapy drug, known as MSB0010718C, meets commercial and regulatory goals.
Thu, Nov. 13, 11:56 AM
- The FDA's Anesthetic and Analgesic Drug Products Advisory Committee meets on November 24, 25 to discuss the risk of serious neurologic adverse reactions associated with epidural steroid injections (ESI) administered to reduce inflammation for pain management. The committee will also review the efficacy of ESI and the overall risk benefit profile of injecting steroids in the epidural space to treat pain. Regulatory options will also be discussed which could include changes to product labeling.
- Briefing doc
- Related tickers: (MRK +0.7%)(PFE +0.2%)(BMY -1.3%)(NVS +2%)
Thu, Nov. 13, 9:01 AMGene mutation targeted by Merck's Zetia leads to lower cholesterol levels and reduced heart disease risk
- Researchers from the Broad Institute and Massachusetts General Hospital identify rare mutations that inactivate a gene the body uses to take cholesterol in food and move it into the bloodstream. The mutations, found in 1 in 650 people, lead to lower cholesterol levels and a reduction in heart disease risk of as much as 50%.
- One of the mutations is the same one targeted by Merck's (NYSE:MRK) Zetia (ezetimibe). The drug works by blocking the absorption of cholesterol in the stomach. Whether the drug can prevent heart attacks and death over and above the use of statins is unclear. A definitive study on the issue, called Improve-It, will be presented at next week's American Heart Association meeting in Chicago. It compares the combination (Merck's Vytorin) of Zetia and the generic cholesterol-lowering drug simvastatin to simvastatin alone.
- There is a high degree of interest in the study results since the failure to prove that Vytorin (and, therefore, Zetia) contributes to a decrease in heart disease and death over and above simvastatin could have a devastating impact on Merck's $4B franchise. FDA guidelines issued last year recommend only those drugs shown to reduce heart attack, stroke and death should be prescribed.
Tue, Nov. 11, 4:52 PM
- A Phase 3 study evaluating Amgen's (NASDAQ:AMGN) brodalumab versus Janssen's (NYSE:JNJ) Stelara (ustekinumab) and placebo at week 12 in patients with moderate-to-severe plaque psoriasis met its primary endpoints. Brodalumab was superior to ustekinumab in achieving total clearance of skin disease as measured by PASI-100. Compared to placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75% improvement from baseline in disease severity at week 12 (measured by PASI-75). All key secondary endpoints were also met.
- Proportion of patients achieving total clearance of disease: brodalumab-210 mg: 36.7%; brodalumab-140 mg: 27.0%; Stelara: 18.5%; placebo: 0.3%.
- Proportion of patients achieving PASI-75: brodalumab-210 mg: 85.1%; brodalumab-140 mg: 69.2%; Stelara: 69.3%; placebo: 6.0%.
- Amgen plans to present the complete results at a future medical conference.
- Related tickers: (NYSE:AZN) (NYSE:GSK) (NASDAQ:CELG) (NYSE:NVS) (NASDAQ:DERM) (NASDAQ:IDRA) (NYSE:HSP) (NYSE:PFE) (NYSEMKT:CANF) (NYSE:MRK)
Tue, Nov. 11, 11:03 AM
- At The Liver Meeting in Boston, Gilead Sciences (GILD +1.1%) presented results from several Phase 2 and Phase 3 trials evaluating Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic HCV infection in patients with limited or no treatment options, including decompensated cirrhosis, HCV recurrence following liver transplantation and patients refractory to other direct-acting antivirals.
- In a pooled analysis of Phase 2 and Phase 3 open-label studies involving more than 500 HCV-1 patients with compensated cirrhosis who received Harvoni alone or with ribavirin (RBV) for 12 or 24 weeks, 96% achieved SVR12.
- In a Phase 2 open-label study evaluating patients with decompensated cirrhosis and those with HCV recurrence after a liver transplant, 87% of those receiving Harvoni + RBV for 12 weeks achieved SVR12 compared to 89% of the treatment arm receiving a 24-week regimen (subgroup analysis of 108 HCV genotype 1 and 4 patients).
- In another subgroup analysis from the same Phase 2 trial, response rates for patients who developed HCV (genotypes 1 and 4) recurrence following liver transplantation who were treated with Harvoni + RBV were analyzed. SVR12 rates for non-cirrhotic patients were 96% and 98%, respectively, for the 12- and 24-week regimens. For patients with compensated cirrhosis, the SVR12 rate was 96% for both regimens. For patients with decompensated cirrhosis, the SVR12 rate was 81% for both regimens.
- In two studies of HCV patients who failed prior therapy, those receiving Harvoni + RBV for 12 weeks achieved SVR12 rates of 96% and 98%. Those receiving Harvoni alone for 24 weeks (Study GS-US-337-0121) achieved an SVR12 rate of 97%.
- HCV-related tickers: (BMY -0.1%)(MRK +1.4%)(ABBV +0.3%)(JNJ +0.2%)(ACHN -0.6%)(RGLS -2.7%)(CNAT -1.1%)(ENTA -0.4%)
Tue, Nov. 11, 10:07 AM
- At The Liver Meeting in Boston, AbbVie (ABBV -0.1%) presented results from studies in HCV patients co-infected with HIV and liver transplant recipients who received its all-oral, interferon-free investigational treatment combining three antivirals (ombitasvir/ABT-450/ritonavir and dasabuvir)
- SVR12 rates for patients co-infected with HCV/HIV that received the company's investigational treatment plus ribavirin were 93.5% for the 12-week regimen and 90.6% for the 24-week regimen.
- In non-cirrhotic liver transplant recipients with recurrent HCV-1 new to treatment, SVR12 and SVR24 rates were each 97.1%.
- HCV-related tickers: (GILD +0.5%)(MRK +1%)(JNJ -0.1%)(BMY -0.2%)(ENTA +0.2%)(RGLS +0.2%)(CNAT -0.5%)(ACHN -1.7%)
Tue, Nov. 11, 9:37 AM
- At The Liver Meeting in Boston, Merck (NYSE:MRK) presented data from a Phase 2 clinical trial evaluating the combination of the company's investigational NS3/4A inhibitor, grazoprevir, and its investigational NS5A inhibitor, elbasvir, with and without ribavirin, in treatment-naive and treatment-experienced HCV-1 patients. The length of treatment was either eight,12 or 18 weeks.
- SVR12 rates in treatment-naive non-cirrhotic patients were: 8-week regimen with RBV: 80%; 12-week regiment with and without RBV: 93% and 98%.
- SVR12 rates in treatment-naive patients with cirrhosis were: 12-week regimen with and without RBV: 90% and 97%; 18-week regimen with and without RBV: 97% and 94%.
- SVR12 rates for treatment-experienced patients with and without cirrhosis: 12-week regimen with and without RBV: 94% and 91%; 18-week regimen with and without RBV: 100% and 97%.
- SVR12 rates for HCV-1 patients co-infected with HIV: 12-week regimen with and without RBV: 97% and 87%.
- Results from a Phase 3 trial are expected in 1H 2015.
- Previously: Merck triple therapy HCV candidate fails as a four-week regimen
- HCV-related tickers: (GILD +0.4%)(JNJ -0.2%)(BMY -0.1%)(ABBV +0.3%)(ACHN +3%)(ENTA +0.4%)(CNAT)(LGND +0.5%)(RGLS)
MRK vs. ETF Alternatives
Company Description
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United States
Other News & PR
See More »


text:
Oxford Town No. 987
IN THIS WEEK'S ISSUE: The late artist Estelle Faulkner will have 19 pieces of her work displayed at the University Museum through October and a reception is planned for July 24 at the museum; Beaver Nelson is set for a show at Proud Larry's on July 19; Adventure author Neal Moore is having a book launch party this Friday (July 13) at the Powerhouse for his new book "Down the Mississippi: A Modern Day Huck on America's River Road;" UM's Center for the Study of Southern Culture is hosting an 80s music night at Barnard Observatory and The Blind Pig on Saturday, July 14; the late Adam Yauch's final documentary "Shut Up and Play the Hits" is set for the Lyric Theater on July 18; and freelance photographer Mike Stanton shares a few of his photos from the wildly successful Hill Country Picnic last weekend in Marshall County. CLICK HERE to download the complete issue in PDF format. (July 12, 2012)
'Modern Day Huck Finn' visits the Powerhouse this Friday (July 13)
OXFORD TOWN – Citizen journalist and up-and-coming author Neal Moore (pictured here) will have his first novel published tomorrow (Friday, July 13) titled "Down the Mississippi: A Modern Day Huck on America's River Road." The adventure author is set for a book launch party at the Powerhouse tomorrow from 5-7 p.m. Page 7 in Oxford Town No. 987 has complete details about the free event and Moore's return to Oxford. (July 12, 2012, Page 7)
Oxford Town No. 986
IN THIS WEEK'S ISSUE: Author Karen White (on the OT cover this week) will visit Off Square Books on July 12 to read from and sign her new, compelling novel "Sea Change;" The 39th Faulkner & Yoknapatawpha Conference begins Saturday, July 7; on Friday, July 6, a full day of Faulkner events are planned to mark the 50th anniversary of the author's death; the Oxford Shakespeare Festival ends this Sunday with a final 2 p.m. staging of "All's Well That Ends Well" at the Ford Center; and the Sleeping Bulls are set for a CD release show and party at Proud Larry's on Saturday July 7. CLICK HERE to download the complete issue in PDF format. (July 5, 2012)
Oxford Town No. 985
IN THIS WEEK'S ISSUE: The North Mississippi Hill country Picnic — its 7th — reloads this weekend in Marshall County just past the Lafayette County line touting its best lineup ever (Robert Belfour pictured on the OT cover); The 2012 Oxford Shakespeare Festival continues this week by staging the enduring musical, "The Sound Of Music;" author RJ Smith will visit Off Square Books on June 30 to discuss and sign his new biography "The One: The Life And Music Of James Brown;" and the city of Oxford celebrates its 175th birthday and the Fourth of July this weekend through the middle of next week. CLICK HERE to download the complete issue in PDF format. (June 28, 2012)
Oxford Town No. 983
IN THIS WEEK'S ISSUE: Still on a major roll for the summer season, Oxford and Lafayette County continue to host tons of art and entertainment events – most of which are family-friendly. America's favorite real life mentalist, The Amazing Kreskin, is set to play two shows at the Lyric Theater on Friday, June 15; Taylor resident Dent May just released his sophomore effort titled "Do Things" and OT contributor Mitch Morgan shares his thoughts about the new album calling it his "summer soundtrack"; Your favorite group of the mid- late-90s – Candlebox – has reunited and are set to open for Daughtry at the Snowden Grove Amphitheater in Southaven on Wednesday, June 20; Gina Sexton and Maybelle's Lovers will play the Summer Sunset Series this Sunday in The Grove as well as Movies in the Park on Friday at Avent Park; and the Oxford Shakespeare Festival kicks off this weekend on the Ole Miss Campus with a production of "All's Well That Ends Well" at the Ford Center on campus. CLICK HERE to download the complete issue in PDF FORMAT. (June 14, 2012)
Oxford Town No. 982
8IN THIS WEEKE'S ISSUE: Who said Oxonians needed the Ole Miss students in town to keep our entertainment scene rolling? Not this week as this OT issue is packed with great events including … Silas Reed 'N' Da Books will play the Summer Sunset Series this Sunday evening in The Grove; The Flaming Lips will attempt to set a world record and the Lyric Theater is one of the band's early stops (June 27) – Grace Potter & The Nocturnals are set to open the show; Pulitzer Prize winning author Richard Ford (on the OT cover this week) will visit Off Square Books June 11 to sign his latest novel, "Canada"; Movies in the Park re-load at Avent Park Friday, June 8 featuring "Toy Story 3″ and the Bays/Guyer Duo; the St. Louis band, Water Liars, are touring in support of its latest album, "Phantom Limb," and the loaded duo are set for a show at The Blind Pig this Friday (June 8). Read about the above events and much more in Oxford Town No. 982. CLICK HERE to download the complete issue in PDF format. (June 7, 2012)
Author Richard Ford set for visit to Off Square Books
OXFORD TOWN – On June 11 at 5 p.m., UM professor and Pulitzer Prize winning author Richard Ford will visit Off Square Books to sign copies of his latest work, "Canada." Page 5 in Oxford Town No. 982 has a review of Ford's "Canada" by new Oxford Town writer and intern Kayleigh Skinner. (June 7, 2012, Page 5)
Oxford Town No. 981
IN THIS WEEK'S ISSUE: The popular, free event, Summer Sunset Series, returns to The Grove Stage this Sunday (June 3) at 7 p.m. featuring Michael Worthy & Friends; Akron, Ohio, native, Joseph Arthur rolls into Oxford for a show at Proud Larry's Saturday, June 2; Oxford Town Sports Columnist Steven Godfrey examines the Rebel baseball team's NCAA Tournament schedule and their chances this weekend; and the Los Angeles-based funk/soul band Orgone is set for a smokin' hot show at Proud Larry's on Friday, June 1. CLICK HERE to download the complete issue in PDF format. (May 31, 2012)
Oxford Town No. 979
IN THIS WEEK'S ISSUE: Lee Bains III & The Glory Fires (on the OT cover this week) roll into Oxford for a free show at Proud Larry's tonight (May 17); Zoogma played and rocked out at the 2012 MIM Beale Street Music Festival and Melanie Addington has post coverage of their amazing set on the banks of the Mississippi River; Hill Country Harmonica returns to Foxfire Ranch for 3 days of blues harp instruction and jam; Fiddler's Loft in Water Valley wraps up its 2012 season tonight at Fiddlin' Rooster Farm; Theatre Oxford's 10 Minute Play winners for 2012 are announced at the Powerhouse; and the May edition of YAC's Oxford Art Crawl is set for Tuesday, May 22. CLICK HERE to download the complete issue in PDF format. (May 17, 2012)
Can I introduce you to William Faulkner?
ONLINE EXCLUSIVE — Approaching William Faulkner's works can be daunting for first-timers. As Oxford prepares to remember the 50th anniversary of Faulkner's death, scholars and fans offer their suggestions for where to begin.
(more…) (May 15, 2012)

subset: commoncrawl


text:
By Catholic Online (NEWS CONSORTIUM)
3/26/2014 (8 months ago)
Catholic Online (www.catholic.org)
There is such a thing as a second chance. The notorious Delaware clinic in which abortionist Kermit Gosnell performed late-term abortions and executed children after birth will see a second life as an emergency food and support center for poor families. Lutheran Community Services purchased the building in Wilmington to serve as its new headquarters.
By Catholic Online (NEWS CONSORTIUM)
Catholic Online (www.catholic.org)
3/26/2014 (8 months ago)
Published in Marriage & Family
Keywords: Dr. Kermit Gosnell, abortion, building
LOS ANGELES, CA (Catholic Online) - Knowing full well of the building's gruesome history - an evil place where poor immigrant women underwent procedures in filthy, dire circumstances and both women and children died, the Christian group intends to turn the building into a place of hope for the less fortunate.
Gosnell, a Philadelphia abortionist who was sentenced to life in prison, used the Delaware facility for utter evil. Gosnell and his assistants would induce illegal, late-term abortions at the Delaware clinic and would then complete them at his west Philadelphia clinic, the Women's Medical Society.
No child need ever go to bed hungry -- go here!
The 73-year-old Gosnell was found guilty of murdering three babies that had been brought to term. A jury also found him guilty of involuntary manslaughter in the drug overdose death of a 41-year-old patient, Karnamaya Mongar.
The Philadelphia clinic was described as a chaotic "house of horrors," with the remains of children in the staff refrigerator, specimen jars of severed feet in his office and dirty medical instruments in the surgery rooms.
It was also the shame of some leaders in the community in which Gosnell operated. Authorities in Pennsylvania had failed to conduct routine inspections of all its abortion facilities for 15 years by the time Gosnell's facility was raided as part of a prescription drug investigation.
The doctor pleaded guilty in federal court to running a pill mill for addicts and drug dealers. Two top state health officials were fired, and the state imposed tougher rules for abortion clinics as a result.
Former clinic employees testified that Gosnell routinely performed illegal abortions past Pennsylvania's 24-week limit. They also testified that Gosnell delivered babies who were still alive. He and his assiatnts would then execute them by snipping their spines with scissors.
The doctor also hired high school dropouts and other unqualified people to engage in these brutal and evil acts. This untrained and inexperienced "doctors" performed abortions, administered anesthesia and monitored high-risk patients.
Gosnell was spared the death penalty after striking a plea deal. He will serve his life sentences consecutively and without parole after giving up his right to appeal.
Marriage Perforated Holy Cards
Prayer Cards
Sacred Heart Of Jesus Holy Card
Prayer Cards
St.joseph Rosary Ring
Biography Of St. Louis De
Prayer Cards
St Jude Holy Card
Prayer Cards
By Catholic Online (NEWS CONSORTIUM)
A doctor in Great Britain has been ordered to appear in court. Forty-six-year-old Dr. Prabha Sivaraman was one of two doctors filmed allegedly agreeing to arrange abortions on account of the gender of the fetus in a 2012 investigation. It's the first such case ... continue reading
By Catholic Online (NEWS CONSORTIUM)
Helen and Joe Auer had been married in 1941. Joe was a proud World War II veteran. Helen bore her husband 10 children. After it was all said and done, they had seen the births of 16 grandchildren, 29 great grandchildren and one great-great grandchild. Helen ... continue reading
By Catholic Online (NEWS CONSORTIUM)
While homosexual marriage remains very much in the news, with homosexuals and lesbians protesting their right to enter marriage, another related trend isn't garnering much attention. Marriage rates among young people in the U.S. are at an all-time low. Many ... continue reading
By Teresa Allen, M.S. Candidate, Clinical Psychology, Institute for the Psychological Sciences
Presently, October 5-19, Pope Francis is leading a Synod of Bishops in an Extraordinary General Assembly in Vatican City to discuss pastoral approaches to matters of family, marriage and evangelization. The theme of the event, "The pastoral challenges of the family in ... continue reading
By Catholic Online (NEWS CONSORTIUM)
Owners of a family farm in New York who were sued because they refused to host a gay wedding on their private property, are asking the courts to reconsider a punitive decision against them. They are asking that their First Amendment rights and their right to religious ... continue reading
By Catholic Online (NEWS CONSORTIUM)
A major pro-life victory for the unborn will see the number of abortion mills in Texas reduced from 40 to just 10. And while that number is still 10 too many, the latest appeals court ruling in Texas represents a small victory for life. LOS ANGELES, CA (Catholic ... continue reading
By Catholic Online (NEWS CONSORTIUM)
A Roman Catholic schoolteacher who says she was fired for trying to become pregnant through in vitro fertilization (IVF) will have her case heard in court following a favorable ruling by a U.S. District Court judge. LOS ANGELES, CA (Catholic Online) - Former Roman ... continue reading
By Catholic Online - (NEWS CONSORTIUM)
The world has a long way to go in regards to respecting its female inhabitants, according to a new United Nations reports. The grim statistics compiled by officials have found that 120 million girls, or slightly more than one in 10 are raped or sexually abused ... continue reading
By Catholic Online - (NEWS CONSORTIUM)
"Amicable divorce," which usually refers to the dissolution of a marriage without bad feelings or upheavals on the part of the parents still do the children no favors. That's the findings of a major study conducted across the United States. LOS ANGELES, CA ... continue reading
By Catholic Online - (NEWS CONSORTIUM)
Approximately 36 percent of the American generation, more than a third, born from 1993 through 2012, due to turn 21 this year, were born to unmarried mothers. According to the Centers for Disease Control, at least 40 percent of the babies born in each of the ... continue reading